Quarter Business Highlights

Principal Financial Data

Fiscal year
(millions of yen)
ending March 2024/Q1 (IFRS) ending March 2024/Q1~2 (IFRS) ending March 2024/Q1~3 (IFRS) ending March 2024/Q1~4 (IFRS) ending March 2025/Q1 (IFRS) ending March 2025/Q1~2 (IFRS) ending March 2025/Year Ended (forecast) (IFRS)
Sales revenue 37,012 73,314 112,728 148,255 39,131 79,332 157,000
 Pharmaceuticals 30,870 60,988 94,606 125,105 33,738 68,496 135,500
 Functional food 6,142 12,325 18,121 23,150 5,393 10,836 21,500
Operating income 11,163 20,878 30,450 33,295 11,078 17,867 33,000
Net income attributable to owners of the parent 8,749 16,176 24,002 25,851 10,264 16,373 30,000
Depreciation and amortization - 2,462 - 5,023 - 2,980 5,800
Capital investment - 3,358 - 6,921 - 2,189 5,500
R&D expenses 5,911 12,517 19,500 31,676 7,497 16,732 33,000
Total assets 237,408 249,499 247,830 263,404 265,828 268,542
Total equity 202,799 211,774 215,316 220,534 227,462 235,252

Sales revenue

Operating income
 

Net income attributable to owners of the parent

R&D expenses

Cash Flows

Fiscal year
(millions of yen)
ending March 2024/Q1 (IFRS) ending March 2024/Q1~2 (IFRS) ending March 2024/Q1~3 (IFRS) ending March 2024/Q1~4 (IFRS) ending March 2025/Q1 (IFRS) ending March 2025/Q1~2 (IFRS)
Cash flow from operating activities 526 7,938 8,126 16,289 7,004 17,732
Cash flow from investing activities △2,060 △1,693 △2,654 △9,921 △6,788 △13,340
Cash flow from financing activities △4,047 △4,685 △9,046 △9,719 △4,328 △4,996

Business Forecast and Outlook

Consolidated business forecast for the fiscal year ending March 2025 (April 1, 2024–March 31, 2025)

Sales revenue Operating income Profit before tax Profit attributable to owners of the parent Basic earnings per share
Consolidated business forecast (millions of yen) 157,000 33,000 33,600 30,000 445.24yen
Year on year rate 5.9 △0.9 △0.0 16.0

(Percentage figures represent year-on-year rate of changes.)